Amphastar Pharmaceuticals (AMPH) Receives Buy Rating from Wells Fargo & Co

Wells Fargo & Co reaffirmed their buy rating on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) in a research note released on Friday, TipRanks reports.

A number of other research analysts also recently issued reports on the stock. BidaskClub upgraded shares of Amphastar Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Friday. TheStreet downgraded shares of Amphastar Pharmaceuticals from a b- rating to a c+ rating in a research report on Monday, March 18th. Needham & Company LLC downgraded shares of Amphastar Pharmaceuticals from a buy rating to a hold rating and set a $22.20 target price on the stock. in a research report on Wednesday, March 13th. Piper Jaffray Companies downgraded shares of Amphastar Pharmaceuticals from an overweight rating to a neutral rating and cut their target price for the company from $24.00 to $23.00 in a research report on Wednesday, March 13th. Finally, Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, March 5th. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $23.73.

Shares of NASDAQ AMPH opened at $20.88 on Friday. The stock has a market cap of $1.01 billion, a P/E ratio of 99.43 and a beta of 1.36. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.41 and a current ratio of 2.06. Amphastar Pharmaceuticals has a 12-month low of $15.01 and a 12-month high of $25.43.



Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Thursday, May 9th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.07. Amphastar Pharmaceuticals had a net margin of 0.74% and a return on equity of 5.28%. The company had revenue of $79.79 million for the quarter, compared to the consensus estimate of $76.21 million. During the same period in the prior year, the company posted $0.05 EPS. The company’s revenue was up 36.7% compared to the same quarter last year. On average, sell-side analysts forecast that Amphastar Pharmaceuticals will post 0.35 earnings per share for the current fiscal year.

In related news, EVP Rong Zhou sold 9,600 shares of the stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $22.76, for a total value of $218,496.00. Following the sale, the executive vice president now directly owns 66,707 shares in the company, valued at approximately $1,518,251.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO William J. Peters sold 1,500 shares of the stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $25.36, for a total transaction of $38,040.00. Following the completion of the sale, the chief financial officer now owns 77,050 shares in the company, valued at $1,953,988. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 100,017 shares of company stock worth $2,233,670. Corporate insiders own 30.80% of the company’s stock.

Several large investors have recently made changes to their positions in AMPH. Federated Investors Inc. PA raised its position in shares of Amphastar Pharmaceuticals by 8.7% in the 1st quarter. Federated Investors Inc. PA now owns 1,472,931 shares of the company’s stock valued at $30,092,000 after acquiring an additional 117,480 shares during the period. Martingale Asset Management L P acquired a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at approximately $2,033,000. Renaissance Technologies LLC raised its position in shares of Amphastar Pharmaceuticals by 104.3% in the 3rd quarter. Renaissance Technologies LLC now owns 186,100 shares of the company’s stock valued at $3,581,000 after acquiring an additional 95,000 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter valued at approximately $1,312,000. Finally, Millennium Management LLC raised its position in shares of Amphastar Pharmaceuticals by 66.3% in the 4th quarter. Millennium Management LLC now owns 140,507 shares of the company’s stock valued at $2,796,000 after acquiring an additional 56,001 shares during the period. Institutional investors and hedge funds own 47.45% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Featured Story: Bollinger Bands

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.